European Journal of Internal Medicine
Volume 20, Issue 5 , Pages 478-481 , September 2009

Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment. Importance of HCC surveillance

  • I. Elefsiniotis

      Affiliations

    • University Department of Internal Medicine, “Elena Venizelou” Hospital, Elena Venizelou Square 2, Athens, Greece
    • Liver Unit and Biochemistry Department, Hospital Universitario Vall d' Hebron, Barcelona, Spain
    • Corresponding Author InformationCorresponding author. Liver Unit and Biochemistry Department, Hospital Universitario Vall d'Hebron, Barcelona, Spain. Tel.: +30 210 9630312; fax: +30 210 7461497.
    • ,
  • M. Buti

      Affiliations

    • Liver Unit and Biochemistry Department, Hospital Universitario Vall d' Hebron, Barcelona, Spain
    • ,
  • R. Jardi

      Affiliations

    • Liver Unit and Biochemistry Department, Hospital Universitario Vall d' Hebron, Barcelona, Spain
    • ,
  • E. Vezali

      Affiliations

    • University Department of Internal Medicine, “Elena Venizelou” Hospital, Elena Venizelou Square 2, Athens, Greece
    • ,
  • R. Esteban

      Affiliations

    • Liver Unit and Biochemistry Department, Hospital Universitario Vall d' Hebron, Barcelona, Spain

Received 29 September 2008 ,Revised 17 November 2008 ,Accepted 18 December 2008.

References 

  1. Lok ASF. Chronic hepatitis B. N Engl J Med. 2002;346:1682–1683
  2. Iloeje U, Yang HI, Su J, Jen CL, You SL, Chen CJ, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678–686
  3. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73
  4. Conjeevaram HS, Lok ASF. Management of chronic hepatitis B. J Hepatol. 2003;38:S90–S103
  5. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A 1 year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339:61–68
  6. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999;341:1256–1263
  7. Shaw T, Bowden S, Locarnini S. Rescue therapy for drug resistant hepatitis B: another argument for combination chemotherapy?. Gastroenterology. 2004;126:343–350
  8. Lai CL, Dienstag JL, Schiff ER, Leung NW, Atkins M, Hunt C, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis. 2003;36:687–696
  9. Lok AS, Lai CL, Leung NW, Yao GB, Cui ZY, Schiff ER, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125:1714–1722
  10. Leung NWY, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology. 2001;33:1527–1532
  11. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003;124:105–117
  12. Liaw YF, Leung NWY, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology. 2000;119:172–180
  13. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen positive chronic hepatitis B. N Engl J Med. 2003;348:808–816
  14. Hadziyannis S, Tassopoulos N, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen negative chronic hepatitis B. N Engl J Med. 2003;348:800–807
  15. Peters MG, Hann HW, Martin P, Heathcote EJ, Buggisch P, Rubin R, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2004;126:91–101
  16. Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology. 2004;126:81–90
  17. Locarnini S, Qi X, Arterbum S, Snow A, Brosgart A, Currie CL, et al. Incidence and predictors of emergence of adefovir resistant HBV during 4 years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (abstract). J Hepatol. 2005;42(Suppl 2):A17
  18. Westland CE, Yang H, Delaney WE, Gibbs CS, Miller MD, Wulfsohn M, et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology. 2003;38:96–103
  19. Lee YS, Suh DJ, Lim YS, Jung SW, Kim KM, Lee HC, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology. 2006;43:1385–1391
  20. Fung SK, Andreone P, Han S, Rajender Reddy K, Regev A, Keeffe EB, et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol. 2005;43:937–943
  21. Fung SK, Chae HB, Fontana R, Conjeevaram H, Marrero J, Oberhelman K, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol. 2006;44:283–290
  22. Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotyping resistance to lamivudine. Hepatology. 2005;42:1414–1419
  23. Papatheodoridis G, Dimou E, Dimakopoulos K, Manolakopoulos S, Rapti I, Kitis G, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analogue therapy starting with lamivudine. Hepatology. 2005;42:121–129
  24. Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis. 2006;26(2):142–152
  25. Pungpapong S, Kim RW, Poterucha JJ. Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clin Proc. 2007;82(8):967–975
  26. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–1531
  27. Buti M, Elefsiniotis I, Jardi R, Vargas V, Rodriguez-Frias F, Schapper M, et al. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine resistant chronic hepatitis B patients. J Hepatol. 2007;47(3):366–372
  28. Yeon JE, Yoo W, Hong SP, Chang YJ, Yu SK, Kim JH, et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut. 2006;55:1488–1495

PII: S0953-6205(08)00344-0

doi: 10.1016/j.ejim.2008.12.013

European Journal of Internal Medicine
Volume 20, Issue 5 , Pages 478-481 , September 2009

Article Tools

* Image Usage & Resolution